Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

Inactivation of LATS1/2 Drives Luminal-Basal Plasticity to Initiate Basal-Like Mammary Carcinomas

December 8, 2022

[Nature Communications] Using genetic mouse models and ex vivo primary organoid cultures, scientists showed that conditional co-deletion of the LATS1 and LATS2 kinases in mature mammary luminal epithelial cells promoted the development of Krt14 and Sox9-expressing basal-like carcinomas that metastasize over time.

Breast Cancer Prevention by Short-Term Inhibition of TGFβ Signaling

December 8, 2022

[Nature Communications] Investigators showed that short-term TGFBR inhibitor treatment of peripubertal ACI inbred and Sprague Dawley outbred rats induced lasting changes and prevented estrogen- and carcinogen-induced mammary tumors, respectively.

FBXL2 Promotes E47 Protein Instability to Inhibit Breast Cancer Stemness and Paclitaxel Resistance

December 8, 2022

[Oncogene] Scientists demonstrated that the F-box protein FBXL2 was a critical negative regulator of breast cancer stem cell stemness and that downregulation of FBXL2 played a causal role in TNBC drug resistance.

RBCK1 Regulates the Progression of ER-Positive Breast Cancer through the HIF1α Signaling

December 8, 2022

[Cell Death & Disease] Investigators identified RBCK1 as an important regulator of hypoxia-inducing factor (HIF) 1α signaling pathway which is activated in breast cancer tumor cells in hypoxia.

Natural Product Preferentially Targets Redox and Metabolic Adaptations and Aberrantly Active STAT3 to Inhibit Breast Tumor Growth In Vivo

December 8, 2022

[Cell Death & Disease] Using TNBC as a model, the authors showed that compared to normal human breast epithelial cells, the TNBC cells, MDA-MB-231 and MDA-MB-468 that harbor constitutively active STAT3 also expressed higher glucose-6-phosphate dehydrogenase, thioredoxin reductase 1, NADPH, and glutathione levels for survival.

Acetylation of Checkpoint Suppressor 1 Enhances Its Stability and Promotes the Progression of Triple-Negative Breast Cancer

December 8, 2022

[Cell Death Discovery] Researchers found that checkpoint suppressor 1 had a high abundance in TNBC and its expression was tightly associated with malignant phenotype and poor outcomes of patients.

Role of Androgen Receptor Signaling Pathway-Related lncRNAs in the Prognosis and Immune Infiltration of Breast Cancer

December 8, 2022

[Scientific Reports] Scientists investigated the effect of the androgen receptor signaling pathway-related long non-coding RNAs (lncRNAs) on the process of subtype classification and the tumor microenvironment of breast cancer.

Transcriptomics Indicate Nuclear Division and Cell Adhesion Not Recapitulated in MCF7 and MCF10A Compared to Luminal A Breast Tumors

December 8, 2022

[Scientific Reports] Investigators performed RNA-seq analyses on a combined dataset of 2D and 3D cultures of tumorigenic MCF7 and non-tumorigenic MCF10A.

Molecular Subtype Conversion in CTCs as Indicator of Treatment Adequacy Associated with Metastasis-Free Survival in Breast Cancer

December 8, 2022

[Scientific Reports] Researchers investigated the molecular subtype discordance between the primary tumor and circulating tumor cells in breast cancer patients.

Breast Cancer Pharmacogenetics: A Systematic Review

December 8, 2022

[Pharmacogenomics] The authors select relevant genes in breast cancer treatment pathways to evaluate treatment response from a pharmacogenetic perspective, and highlight polymorphism frequencies and ethnic and continental representation of breast cancer.

Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit versus Faslodex

December 8, 2022

[AstraZeneca] SERENA-2 Phase II trial showed AstraZeneca’s camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival at both 75mg and 150mg dose levels versus Faslodex 500mg in post-menopausal patients with estrogen receptor (ER)-positive locally advanced or metastatic breast cancer.

Laminin Matrix Adhesion Regulates Basal Mammary Epithelial Cell Identity

December 8, 2022

[Journal of Cell Science] Researchers showed that adhesion of basal cells to laminin α5-containing basement membrane matrix, which was produced by luminal cells, presented a regulated control mechanism to restrict excess basal cell activity.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.